Avidity Partners Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Avidity Partners Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-206,000	Closed	-$65.2M	–	107
2023 Q4	$65.2M	Sell	206,000 -80,700	-28%	-$15.7M	2.38%	11
2023 Q3	$48.5M	Sell	286,700 -155,500	-35%	-$29.2M	1.95%	15
2023 Q2	$95.9M	Buy	442,200 +38,400	+10%	+$8.23M	3.35%	2
2023 Q1	$73.3M	Buy	403,800 +104,800	+35%	+$20M	2.43%	14
2022 Q4	$58.8M	Sell	299,000 -132,800	-31%	-$28.5M	1.27%	28
2022 Q3	$97.1M	Buy	431,800 +227,230	+111%	+$46M	1.97%	18
2022 Q2	$25.9M	Buy	+204,570	New	+$23.5M	0.59%	36

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Avidity Partners Management's KRTX Position: Q1 2024 in Review

Avidity Partners Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 206,000 shares — an estimated $65.2M sold.

Avidity Partners Management first reported a position in KRTX in Q2 2022 and held it in 7 quarters. The position peaked at $97.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Avidity Partners Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Avidity Partners Management sold 206,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $65.2M.
Avidity Partners Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Avidity Partners Management's Karuna Therapeutics, Inc. Common Stock position peaked at $97.1M in Q3 2022.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.